Friday 6 November 2026
Export LH’s income statement to Excel — free account
Labcorp Holdings Inc.
LH Healthcare Diagnostics & Research
Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024.
- Revenue
- +6.92%
- EPS
- +3.18%
- Free cash flow
- +44.7%
- Total debt
- +3.21%
Quarter to September 2026, against a year earlier
362.28
5.51
−1.50%
Follow LH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
8 | 7 | 8 | 7 |
| 10.51% | 11.05% | 11.74% | 11.45% | ||
| 4.77% | 5.13% | 5.48% | 5.40% | ||
ROIC |
6.54% | 6.59% | 6.50% | 6.76% | |
Return on Tangible Assets |
20.49% | 18.89% | 20.92% | 23.41% | |
Average Days of Receivables |
59.14 | 63.24 | 63.72 | 63.99 | |
Free Cash Flow per Share |
14.59 | 17.00 | 14.33 | 15.97 | |
Free Cash Flow |
1,214.00 | 1,399.30 | 1,170.50 | 1,294.90 | |
Capital Expenditures |
(426.50) | (414.20) | (467.90) | (520.10) | |
| Other line items | |||||
Cash ROIC |
8.49% | 8.97% | 7.98% | 8.98% | |
Accounts Receivable Turnover |
6.40 | 5.99 | 6.00 | 6.05 | |
Accounts Payable Turnover |
11.58 | 14.24 | 13.78 | 14.74 | |
Inventory Turnover |
19.34 | 20.42 | 19.07 | 19.56 | |
Average Days of Payables |
30.88 | 25.23 | 24.63 | 25.98 | |
Days of Inventory on Hand |
19.64 | 18.05 | 20.11 | 18.96 | |
Tax Rate |
(0.21) | (0.18) | (0.19) | (0.18) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15.89% | 15.70% | 15.47% | 15.61% | |
Share Based Compensation of Revenue |
0.90% | 0.88% | 0.87% | 0.87% | |
Interest Coverage |
6.18 | 6.45 | 6.59 | 6.52 | |
Operating CF/Net income |
1.87 | 1.93 | 1.63 | 1.81 | |
Depreciation/Fixed assets |
0.22 | 0.22 | 0.22 | 0.22 | |
Capex/Depreciation |
(0.63) | (0.60) | (0.67) | (0.74) | |
Revenue per Share |
167.69 | 171.86 | 175.62 | 179.96 | |
Operating CF per Share |
19.72 | 22.04 | 20.05 | 22.38 | |
Capex per Share |
(5.13) | (5.03) | (5.73) | (6.41) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 |
Columns are period end dates · fundamentals updated 5 Nov 2026